Clinical Trial Finder

Inclusion Criteria:

General Inclusion Criteria ModA Part 1 and 2:

• - Able to take oral medication.

• - If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements.

• - Adequate organ function and electrolytes.

• - Eastern Cooperative Oncology Group Performance Status (ECOG-PS) of 0 to 1 at Screening.

• - Has a life expectancy of more than 6 months.

• - In addition to these general inclusion criteria, participants must meet all the module cohort-specific inclusion criteria.

Inclusion Criteria ModA Part 1 Cohort Specific:

• - Pathologically confirmed diagnosis of solid cancer and documentation of Kirsten rat sarcoma (KRAS), Harvey rat sarcoma virus (HRAS), neuroblastoma ras viral oncogene homolog (NRAS), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), v-raf murine sarcoma viral oncogene homolog C1(CRAF), and/or neurofibromatosis 1 (NF1) mutation.

• - Have exhausted all available standard of care therapies that are known to provide benefit for the participant's condition, as judged by the Investigator.

Inclusion Criteria ModA Part 2 Cohort Specific:

• - Documented BRAF gene mutation.

• - Pathologically confirmed diagnosis with PD after at least one prior line of therapy in the advanced or metastatic setting.

Exclusion Criteria:

General Exclusion Criteria ModA Part 1 and 2:

• - Prior treatment with certain BRAF dimer inhibitors.

• - Female participant is pregnant or lactating.

• - Received any prior or concurrent medications or therapies known to be prohibited with DCC-3084 within 14 days.

• - Received any prior antitumor therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-3084.

• - Known allergy or hypersensitivity to any component of the study drug.

• - Invasive malignancy within 2 years prior to the first dose of study drug other than the study indication or specific types of cancer treated with curative intent.

• - Have not recovered from all clinically relevant toxicities from prior therapy.

• - Impaired cardiac function.

• - History of recent thrombotic or embolic events.

• - Malabsorption syndrome or other illness that could affect oral absorption.

• - Major surgery within 28 days of the first dose of study drug.

• - In addition to the general exclusion criteria, participants will also be excluded based on the cohort-specific exclusion criteria.

Exclusion Criteria:

Module A Part 2 Cohort Specific: • Has known co-occurring mutation of KRAS, HRAS, NRAS, NF1, epidermal growth factor receptor, Phosphoinositide-3-kinase, catalytic, alpha polypeptide (PI3KCA), or Phosphatase and TENsin homolog deleted on chromosome 10 (PTEN)

Arms

Experimental: DCC-3084 Module A Escalation Phase (ModA Part 1)

Participants will receive DCC-3084 in ModA Part 1, Escalation Phase.

Experimental: DCC-3084 Module A Expansion Phase (ModA Part 2)

Participants will receive DCC-3084 in ModA Part 2, Expansion Phase.

Interventions

Drug: - DCC-3084

Administered orally